Study of tafenoquine for chronic babesiosis with fatigue
Treatments studied
Part of Infections clinical trials.
This study tests an oral medication, tafenoquine, to see if it helps people with chronic babesiosis who have ongoing fatigue and other symptoms. It aims to find a better treatment for this tick-borne infection that keeps coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have severe fatigue that makes daily life hard
- You have at least one common symptom of babesiosis (such as fever, chills, headache, or muscle aches)
- A lab test in the last year showed that you were exposed to Babesia
- You cannot have G6PD deficiency (a genetic red blood cell condition)
- You cannot have certain other medical conditions like HIV, hepatitis, or uncontrolled heart/lung problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding the oral drug tafenoquine to standard care works better than standard care plus a placebo for treating babesiosis, a tick-borne illness. You must be hospitalized with active symptoms.
This study tests how the body processes a single dose of the antimalarial drug tafenoquine in healthy adults. It will help doctors understand how the drug works and how it is broken down, which may lead to better ways to prevent malaria.
This trial tests a revised dose of a medicine called tafenoquine to more effectively cure vivax malaria (a type of malaria that can come back). It is for people with normal G6PD enzyme levels and a current fever from vivax malaria.
This study tests the best dose of tafenoquine to treat people with symptoms from a malaria type called P. vivax and to help prevent it from coming back. You may be eligible if you recently had fever and meet specific blood and safety checks, especially G6PD level.
This trial tests whether adding the drug tafenoquine to standard malaria treatment can prevent the return of P. vivax malaria. It is for adults who have a normal G6PD enzyme level and are healthy enough to participate.
This study tests how the malaria medicine tafenoquine works in healthy children in Papua New Guinea. It may help find the right dose to prevent malaria safely.
Hear when a new Chronic Babesiosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.